Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 225,369,715 papers from all fields of science
Search
Sign In
Create Free Account
alizapride
Known as:
N-((1-Allyl-2-Pyrrolidinyl)Methyl)-6-Methoxy-1H-Benzotriazole-5-Carboxamide
, Alizaprida
, Alizapridum
Expand
A substituted benzamide that acts as a dopamine receptor antagonist with antiemetic properties.
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
6 relations
Broader (2)
Antiemetics
Pyrrolidines
Narrower (4)
MS 5080
Plitican
Vergentan
alizapride hydrochloride
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
Alizapride and ondansetron for the prevention of postoperative nausea and vomiting in patients undergoing laparoscopic gynaecological surgery: A double-blind, randomised, placebo-controlled…
G. Dewinter
,
A. Teunkens
,
+7 authors
S. Rex
European Journal of Anaesthesiology
2016
Corpus ID: 13269061
BACKGROUND Postoperative nausea and vomiting (PONV) can be prevented. Alizapride is an established antiemetic that may be…
Expand
1996
1996
Determination of unbound etoposide concentration in ultrafiltered plasma by high-performance liquid chromatography with fluorimetric detection.
I. Robieux
,
P. Aita
,
R. Sorio
,
G. Toffoli
,
M. Boiocchi
Journal of chromatography. B, Biomedical…
1996
Corpus ID: 26338909
1994
1994
Emesis induced in domestic pigs: a new experimental tool for detection of antiemetic drugs and for evaluation of emetogenic potential of new anticancer agents.
I. Szelenyi
,
H. Herold
,
M. Göthert
Journal of pharmacological and toxicological…
1994
Corpus ID: 21074326
1992
1992
Comparison of three protracted antiemetic regimens for the control of delayed emesis in cisplatin-treated patients.
Isabel Moreno
,
Rafael Rosell
,
+5 authors
Albert Font
European Journal of Cancer
1992
Corpus ID: 10070304
1992
1992
Fractionated chemotherapy : granisetron or conventional antiemetics ?
V. Diehl
1992
Corpus ID: 73322614
1990
1990
Alizapride in the prevention of post-thyroidectomy emetic sequelae
M. Dejonckheere
,
T. Deloof
,
Nele Dustin
,
P. Ewalenko
1990
Corpus ID: 69133215
Two-hundred patients scheduled for elective thyroidectomy under halothane-nitrous-oxide-oxygen anaesthesia were randomly divided…
Expand
Highly Cited
1986
Highly Cited
1986
Droperidol, alizapride and metoclopramide in the prevention and treatment of post-operative emetic sequelae.
A. Kauste
,
M. Tuominen
,
H. Heikkinen
,
A. Gordin
,
K. Korttila
European Journal of Anaesthesiology
1986
Corpus ID: 22740376
Women (182) undergoing elective orthopaedic surgery under general anaesthesia received 100 or 200 mg alizapride, 1.25 mg…
Expand
1986
1986
The antiemetic activity of high‐dose alizapride and high‐dose metoclopramide in patients receiving cancer chemotherapy: A prospective, randomized, double‐blind trial
R. Joss
,
R. Galeazzi
,
A. Bischoff
,
M. Pirovino
,
H. Ryssel
,
K. Brunner
Clinical pharmacology and therapy
1986
Corpus ID: 42210275
Alizapride is a new substituted benzamide with suggested superior antiemetic efficacy to and fewer side effects than…
Expand
1985
1985
Comparison of the antiemetic efficacy of two high-dose benzamides, metoclopramide and alizapride, against cisplatin-induced emesis.
R. Saller
,
D. Hellenbrecht
Cancer treatment reports
1985
Corpus ID: 7271745
The antiemetic effect of two benzamides, metoclopramide (MCL; Paspertin) and alizapride (AZP; Vergentan), was compared in two…
Expand
1985
1985
High-dose alizapride versus high-dose domperidone: a double-blind comparative study in the management of cis-platinum-induced emesis.
J. Huys
,
M. Troch
,
R. P. Bourguignon
,
P. Smets
Current Medical Research and Opinion
1985
Corpus ID: 32428055
A double-blind, randomized crossover trial was carried out in 44 cancer patients receiving chemotherapy with cis-platinum to…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE